Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIODESIX INC Director's Dealing 2020

Oct 28, 2020

34472_dirs_2020-10-27_be6db81a-f343-486b-bd79-372214302f42.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BIODESIX INC (BDSX)
CIK: 0001439725
Period of Report: 2020-10-27

Reporting Person: SCHULER JACK W (Director, 10% Owner)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Series B Preferred Stock $ Common Stock (245042) Indirect
Series B-1 Preferred Stock $ Common Stock (245041) Indirect
Series C Preferred Stock $ Common Stock (56155) Indirect
Series D Preferred Stock $ Common Stock (522546) Indirect
Series E Preferred Stock $ Common Stock (296476) Indirect
Series F Preferred Stock $ Common Stock (1056921) Indirect
Series G Preferred Stock $ Common Stock (1586846) Indirect
Series H Preferred Stock $ Common Stock (904060) Indirect
3% Convertible Debt due June 2021 $ 2021-06-30 Common Stock (753735) Indirect
Stock Options (Right to Buy) $6.83 2029-07-15 Common Stock (35158) Direct
Stock Options (Right to Buy) $6.83 2030-04-14 Common Stock (35158) Direct

Footnotes

F1: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") is convertible into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") upon the closing of the Issuer's initial public offering ("IPO"). Share numbers give effect to such conversion. The Preferred Stock has no expiration date.

F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.

F3: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") is convertible into approximately 0.196 shares of Common Stock. Share numbers give effect to such conversion. The B-1 Preferred Stock has no expiration date.

F4: This Convertible Debt pays interest at 3% per annum and is payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt is unpaid, the outstanding principal and unpaid accrued interest shall be automatically converted into Common Stock at the completion of the IPO. The conversion price will be equal to 80% of the price per share paid for the Common Stock sold in the IPO. The conversion price is $14.40, or 80% of the $18 price per share paid for the Common Stock sold in the IPO.

F5: This option vested in 12 successive, equal monthly installments measured from April 1, 2019.

F6: This option vests in 12 successive, equal monthly installments measured from April 1, 2020.